WEDNESDAY, Nov. 30, 2022 (HealthDay News) — The experimental Alzheimer’s drug lecanemab slowed thinking declines among patients suffering the early stages of the disease in a new study, but safety concerns about brain swelling and brain bleeds remain. In the eagerly awaited trial findings, published Tuesday in the New EnglandContinue Reading

TUESDAY, Nov. 29, 2022 (HealthDay News) — Two people have now died from brain hemorrhages that may be linked to an experimental Alzheimer’s drug, calling into question the medication’s safety. A 65-year-old woman with early-stage Alzheimer’s recently died from a massive brain bleed that some researchers link to lecanemab, anContinue Reading

SUNDAY, Nov. 13, 2022 (HealthDay News) — While most homes aren’t designed to be dementia-friendly, they can easily be adapted, according to a national Alzheimer’s disease group. “Virtually every aspect of a home can affect the person’s quality of life,” said Charles Fuschillo Jr., president and CEO of the Alzheimer’sContinue Reading